Document AbbVie Inc. Guidance Including the Impact of Acquired IPR D and Milestones Expense (Unaudited) (in millions, except per share data) Quarter Ended
Tuesday, March 31, 2026 1 min read
Key Takeaway: AbbVie Inc. has updated its guidance for the first quarter and full year of 2026, factoring in acquired IPR D and milestones expense. The adjusted diluted EPS for Q1 2026 is projected between $2.56 and $2.60, reflecting a significant expense of $744 million. For the full year, the guidance indicates an adjusted diluted EPS range of $13.96 to $14.16. Notably, the company's guidance excludes any potential expenses incurred after the first quarter, underscoring the uncertainty of future financial impacts.
Market Sentiment Analysis
POSITIVE FACTORS
AbbVie has provided updated guidance for Q1 and full-year 2026.
The adjusted diluted EPS is projected to be within a favorable range.
Specific financial figures have been disclosed, enhancing transparency.
CONCERNS & RISKS
The impact of acquired IPR D and milestones expense is significant, reducing EPS.
Certain expenses beyond Q1 2026 cannot be reliably forecasted.
Full Press Release Details
Guidance Including the Impact of Acquired IPR D and Milestones Expense
(in millions, except per share data)
Quarter Ended March 31, 2026
Full-Year Ended December 31, 2026
Acquired IPR D and Milestones Expense
Adjusted Diluted EPS Range
Acquired IPR D and Milestones Expense
Adjusted Diluted EPS Range
Low
High
Low
High
Previously announced guidance excluding Q1 2026 acquired IPR D and milestones expense
$
-
$
2.97
$
3.01
$
-
$
14.37
$
14.57
Q1 2026 acquired IPR D and milestones expense
744
(0.41)
(0.41)
744
(0.41)
(0.41)
Guidance including Q1 2026 acquired IPR D and milestones expense a
$
744
$
2.56
$
2.60
$
744
$
13.96
$
14.16
a The Company's 2026 adjusted diluted EPS guidance excludes any impact from acquired IPR D and milestones expense that may be incurred beyond the first quarter of 2026, as both cannot be reliably forecasted.
Frequently Asked Questions
What was the Q1 2026 acquired IPR D expense?
The acquired IPR D and milestones expense for Q1 2026 was $744 million.
How does Q1 2026 impact the adjusted EPS range?
Including the Q1 2026 expense, the adjusted EPS range is $2.56 to $2.60.
What was the previously announced adjusted EPS range?
The previously announced adjusted EPS range was $2.97 to $3.01.
What is the full-year adjusted EPS guidance?
For the full year 2026, the adjusted EPS guidance is $13.96 to $14.16.
Does the 2026 guidance include future IPR D expenses?
The guidance excludes any future acquired IPR D expenses beyond Q1 2026.